期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 20, 期 8, 页码 1847-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2021.10.029
关键词
Hypnotherapy; Functional Nausea; Children; RCT
资金
- Dutch Digestive Foundation
- Christine Bader Foundation
Gut-directed hypnotherapy (HT) is effective in reducing chronic nausea symptoms in children, especially in those with functional nausea.
BACKGROUND & AIMS: The potential effectiveness of gut-directed hypnotherapy (HT) is unknown for pediatric chronic nausea. This randomized controlled trial compared HT with standard medical treatment (SMT). METHODS: One hundred children (ages, 8-18 y) with chronic nausea and fulfilling functional nausea (FN) or functional dyspepsia (FD) criteria were allocated randomly (1:1) to HT or SMT, with a 3month intervention period. Outcomes were assessed at baseline, at the halfway point, after treatment, and at the 6- and 12-month follow-up evaluation. Children scored nausea symptoms in a 7-day diary. The primary outcome was treatment success, defined as a reduction in nausea of 50% or more, at the 12-month follow-up evaluation. Secondary outcomes included adequate relief of nausea. RESULTS: After treatment and at the 6-month follow-up evaluation, there was a trend toward higher treatment success in the HT group compared with the SMT group (45% vs 26%, P =.052; and 57% vs 40%, P =.099, respectively). At 12 months, treatment success was similar in both groups (60% in the HT group and 55% in the SMT group; P =.667). In the FN group, significantly higher success rates were found for HT, but no differences were found in patients with FD. Adequate relief was significantly higher in the HT group than in the SMT group at the 6month follow-up evaluation (children: 81% vs 55%, P =.014; parents: 79% vs 53%; P =.016), but not at the 12-month follow-up evaluation. CONCLUSIONS: HT and SMT were effective in reducing nausea symptoms in children with FN and FD. In children with FN, HT was more effective than SMT during and after the first 6 months of treatment. Therefore, HT and SMT, applied separately or in combination, should be offered to children with FN as a treatment option (Clinical trials registration number: NTR5814).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据